

UCLA

UCLA Previously Published Works

Title

Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network - 12 States, April-August 2020.

Permalink

<https://escholarship.org/uc/item/4638k1w2>

Journal

MMWR. Morbidity and mortality weekly report, 69(47)

ISSN

0149-2195

Authors

Self, Wesley H
Tenforde, Mark W
Stubblefield, William B
[et al.](#)

Publication Date

2020-11-01

DOI

10.15585/mmwr.mm6947a2

Peer reviewed

Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network — 12 States, April–August 2020

Wesley H. Self, MD^{1,*}; Mark W. Tenforde, MD, PhD^{2,*}; William B. Stubblefield, MD¹; Leora R. Feldstein, PhD²; Jay S. Steingrub, MD³; Nathan I. Shapiro, MD⁴; Adit A. Ginde, MD⁵; Matthew E. Prekker, MD⁶; Samuel M. Brown, MD⁷; Ithan D. Peltan, MD⁷; Michelle N. Gong, MD⁸; Michael S. Aboodi, MD⁸; Akram Khan, MD⁹; Matthew C. Exline, MD¹⁰; D. Clark Files, MD¹¹; Kevin W. Gibbs, MD¹¹; Christopher J. Lindsell, PhD¹; Todd W. Rice, MD¹; Ian D. Jones, MD¹; Natasha Halasa, MD¹; H. Keipp Talbot, MD¹; Carlos G. Grijalva, MD¹; Jonathan D. Casey, MD¹; David N. Hager, MD, PhD¹²; Nida Qadir, MD¹³; Daniel J. Henning, MD¹⁴; Melissa M. Coughlin, PhD²; Jarad Schiffer, MS²; Vera Semenova, PhD²; Han Li, PhD²; Natalie J. Thornburg, PhD^{2,*}; Manish M. Patel, MD^{2,*}; CDC COVID-19 Response Team; IVY Network

Most persons infected with SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), develop virus-specific antibodies within several weeks, but antibody titers might decline over time. Understanding the timeline of antibody decline is important for interpreting SARS-CoV-2 serology results. Serum specimens were collected from a convenience sample of frontline health care personnel at 13 hospitals and tested for antibodies to SARS-CoV-2 during April 3–June 19, 2020, and again approximately 60 days later to assess this timeline. The percentage of participants who experienced seroreversion, defined as an antibody signal-to-threshold ratio >1.0 at baseline and <1.0 at the follow-up visit, was assessed. Overall, 194 (6.0%) of 3,248 participants had detectable antibodies to SARS-CoV-2 at baseline (1). Upon repeat testing approximately 60 days later (range = 50–91 days), 146 (93.6%) of 156 participants experienced a decline in antibody response indicated by a lower signal-to-threshold ratio at the follow-up visit, compared with the baseline visit, and 44 (28.2%) experienced seroreversion. Participants with higher initial antibody responses were more likely to have antibodies detected at the follow-up test than were those who had a lower initial antibody response. Whether decay in these antibodies increases risk for reinfection and disease remains unanswered. However, these results suggest that serology testing at a single time point is likely to underestimate the number of persons with previous SARS-CoV-2 infection, and a negative serologic test result might not reliably exclude prior infection.

Once infected with SARS-CoV-2, most persons develop virus-specific antibodies within 2–3 weeks (2,3). Serology tests are now being used widely in seroprevalence studies to understand patterns of viral spread, cumulative incidence of SARS-CoV-2 infection, and pandemic trajectory (4–6). Further, serologic testing has been proposed as a way to identify persons who might have developed immunity through a previous infection. Understanding how rapidly SARS-CoV-2 antibody levels decline after seroconversion is critical for interpreting serology results. A limited number of studies have

found declines in SARS-CoV-2 antibody levels over time (7–9), but the frequency and timing of seroreversion (the decline in antibody levels below the positivity threshold after initial seroconversion) remains largely unknown.

The Influenza Vaccine Effectiveness in the Critically Ill (IVY) Network, a collaboration of academic medical centers in the United States that studies influenza and COVID-19 (1), enrolled a convenience sample of frontline health care personnel at 13 centers in 12 states,[†] with a target of 250 participants per center. Health care personnel were eligible if they reported regular direct contact with COVID-19 patients and worked in the emergency department, intensive care unit, or other hospital-based unit that cared for patients with COVID-19. Participants underwent two study visits: a baseline visit (conducted April 3–June 19, 2020) and a follow-up visit approximately 60 days after the baseline visit. At both visits, blood was collected for SARS-CoV-2 antibody testing, and participants were questioned about demographic characteristics, underlying medical conditions, signs or symptoms of an acute viral infection from February 1, 2020, until the visit date,[§] and any previous SARS-CoV-2 testing (e.g., reverse transcription–polymerase chain reaction [RT-PCR]) for acute infection. Blood specimens collected at the baseline and follow-up visits were tested for SARS-CoV-2 antibodies at CDC using an enzyme-linked immunosorbent assay (ELISA) against the extracellular domain of the SARS-CoV-2 spike protein (4). The assay detects all SARS-CoV-2 immunoglobulin (Ig) types (IgA, IgM, or IgG). Specimens were considered reactive with a signal-to-threshold ratio >1.0 at a background corrected

[†] Participating academic medical centers and their locations were Harborview Medical Center (Washington), Oregon Health & Science University (Oregon), University of California Los Angeles (California), Hennepin County Medical Center (Minnesota), Vanderbilt University Medical Center (Tennessee), Ohio State University (Ohio), Wake Forest University (North Carolina), Montefiore Medical Center (New York), Beth Israel Deaconess Medical Center (Massachusetts), Baystate Medical Center (Massachusetts), Intermountain Medical Center (Utah), UCHealth University of Colorado Hospital (Colorado), and Johns Hopkins Hospital (Maryland).

[§] Previous signs and symptoms included one or more of the following: fever (temperature >99.5°F [37.5°C]), cough, shortness of breath, myalgias, sore throat, vomiting, diarrhea, change in or loss of taste, change in or loss of smell, chest tightness.

*Wesley H. Self and Mark W. Tenforde contributed equally to this report; Manish M. Patel and Natalie J. Thornburg contributed equally to this report.

serum dilution of 1:100, with higher ratios indicating higher antibody titers. The assay has a sensitivity estimated at 96% and specificity at 99% (4).

The change in signal-to-threshold ratio between the baseline visit and follow-up visit was quantified, and the percentage of participants who experienced seroreversion was reported. Logistic regression was used to evaluate the association between baseline signal-to-threshold value and seroreversion, adjusting for age, sex, race/ethnicity, number of days between the baseline and follow-up visit, and presence of one or more chronic medical condition. Analyses were conducted using Stata (version 16; StataCorp). The project was determined to be nonresearch public health surveillance by participating institutions and CDC and was conducted consistent with applicable federal law and CDC policy.¶

Among 3,248 health care personnel, 194 (6.0%) had antibodies to SARS-CoV-2 at the baseline visit (1). Among these, 156 (80.4%) returned for the follow-up visit around 60 days later (range = 50–91 days). Among these 156 participants with a positive baseline serology and follow-up antibody testing performed, median age was 38 years (interquartile range [IQR] = 30–48 years), 94 (60.3%) were female, and 108 (69.2%) reported one or more symptoms of an acute infection consistent with COVID-19 between February 1, 2020 and the baseline visit. Among the 108 participants who reported symptoms, the median interval between symptom onset and baseline serology testing was 30 days (IQR = 19–40 days). Participants who reported symptoms of an acute viral illness since February had higher baseline signal-to-threshold ratios (median = 3.6; IQR = 3.1–3.9) than did those who did not report symptoms (median = 2.5; IQR = 1.5 to 3.6) ($p < 0.001$). Among these 156 participants, 72 (46.2%) reported past RT-PCR testing for SARS-CoV-2, 46 (63.9%) of whom had positive test results; no hospitalizations were reported.

Among the 156 participants who returned for follow-up, the signal-to-threshold value for 146 (93.6%) had declined since the baseline visit, including 44 (28.2%) participants who experienced seroreversion (Table 1) (Supplementary Figure, <https://stacks.cdc.gov/view/cdc/97358>), with antibody levels falling below the threshold for positivity. Among 108 participants who reported previous COVID-19-compatible signs or symptoms, 21 (19.4%) seroreverted, compared with 23 (47.9%) of 48 of participants who did not report symptoms ($p < 0.001$). Among 72 participants with previous RT-PCR testing, one (2.2%) of 46 with a positive test result versus seven (26.9%) of 26 with a negative test result seroreverted. Seroreversion occurred in 64.9% (37 of 57) of participants with a low antibody response

TABLE 1. Antibody signal-to-threshold ratio of panimmunoglobulin reactivity to SARS-CoV-2 full length S protein enzyme-linked immunosorbent assay among frontline health care personnel from a baseline visit (April–June 2020) to a follow-up visit approximately 60 days later,* overall and by baseline antibody level (N = 156) — 13 academic medical centers,† United States, April–August, 2020

| Baseline signal-to-threshold ratio | No. | Baseline signal-to-threshold ratio, median (IQR) | Follow-up signal-to-threshold ratio, median (IQR) | No. (%) who seroreverted |
|------------------------------------|-----|--|---|--------------------------|
| All | 156 | 3.4 (2.3–3.8) | 2.6 (0.9–3.2) | 44 (28.2) |
| Low positive (1.0–2.9) | 57 | 1.6 (1.3–2.4) | 0.8 (0.5–1.2) | 37 (64.9) |
| High positive (≥ 3) | 99 | 3.7 (3.5–5.3) | 3.1 (2.6–3.3) | 7 (7.1) |

Abbreviation: IQR = interquartile range.

* Range = 50–91 days. The population included 156 frontline health care personnel in the United States from 13 academic medical centers in 12 states who tested positive for SARS-CoV-2 antibodies (signal-to-threshold > 1.0) at the baseline visit and underwent repeat testing at the follow-up visit.

† Harborview Medical Center (Washington), Oregon Health & Science University (Oregon), University of California Los Angeles (California), Hennepin County Medical Center (Minnesota), Vanderbilt University Medical Center (Tennessee), Ohio State University (Ohio), Wake Forest University (North Carolina), Montefiore Medical Center (New York), Beth Israel Deaconess Medical Center (Massachusetts), Baystate Medical Center (Massachusetts), Intermountain Medical Center (Utah), UHealth University of Colorado Hospital (Colorado), and Johns Hopkins Hospital (Maryland).

(baseline signal-to-threshold value = 1.0–2.9) and 7.1% (seven of 99) of participants with a high antibody response (baseline signal-to-threshold value ≥ 3.0) ($p < 0.001$) (Figure). A higher baseline signal-to-threshold ratio was associated with lower odds of seroreversion at the follow-up visit (adjusted odds ratio [aOR] for a 1-unit increase in signal-to-threshold ratio = 0.29; 95% CI = 0.18–0.46) (Table 2). In this model, a 10-year increase in participant age was associated with higher odds of seroreversion (aOR = 1.74; 95% CI = 1.06–2.85). Compared with non-Hispanic White participants, odds of seroreversion were lower among non-Hispanic Black participants (aOR = 0.11; 95% CI = 0.15–0.76) and Hispanic participants (aOR = 0.10; 95% CI = 0.01–0.88).

Discussion

In this study of 156 frontline U.S. health care personnel who received positive SARS-CoV-2 antibody test results in spring 2020 and returned for follow-up testing approximately 60 days later, 146 (93.6%) had a decline in antibody levels between baseline and follow-up, and 44 (28.2%) had complete seroreversion, i.e., a decline of antibody to levels below the threshold for positivity. A higher percentage of those with low baseline antibody levels seroreverted (64.9%) than did those with high baseline titers (7.1%). These results suggest that a substantial proportion of persons infected with SARS-CoV-2 might have negative serologic test results in the months following infection. This has several important implications. Cross-sectional seroprevalence studies that estimate the number of

¶ 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 501 et seq.

TABLE 2. Baseline characteristics associated with SARS-CoV-2 seroreversion (multivariable logistic regression model)* among frontline health care personnel† (N = 156) — 13 academic medical centers, United States, 2020[§]

| Characteristic | Odds ratio (95% CI) | |
|---|---------------------|-----------------------|
| | Unadjusted | Adjusted [¶] |
| Signal-to-threshold ratio at baseline visit, 1-unit change** | 0.34 (0.23–0.51) | 0.29 (0.18–0.46) |
| Age, 10-yr change ^{††} | 1.13 (0.83–1.55) | 1.74 (1.06–2.85) |
| Time from baseline visit to follow-up visit antibody testing, 1-wk change ^{§§} | 1.66 (1.24–2.21) | 2.23 (1.46–3.40) |
| Female sex | 0.93 (0.46–1.90) | 1.49 (0.49–4.50) |
| Race/Ethnicity | | |
| White, non-Hispanic | Referent | Referent |
| Black, non-Hispanic | 0.24 (0.07–0.88) | 0.11 (0.15–0.76) |
| Hispanic or Latino | 0.21 (0.05–0.98) | 0.10 (0.01–0.88) |
| Other | 0.42 (0.13–1.38) | 0.37 (0.08–1.59) |
| ≥1 baseline medical condition ^{¶¶} | 1.44 (0.61–3.40) | 2.70 (0.74–9.94) |

Abbreviation: CI = confidence interval.

* A seropositive result (signal-to-threshold >1.0) at the baseline visit in the spring of 2020 and a seronegative result (signal-to-threshold <1.0) at the follow-up visit approximately 60 days later.

† Persons who tested positive for SARS-CoV-2 antibodies (signal-to-threshold >1.0) at the baseline visit and underwent repeat testing at the follow-up visit.

§ Harborview Medical Center (Washington), Oregon Health & Science University (Oregon), University of California Los Angeles (California), Hennepin County Medical Center (Minnesota), Vanderbilt University Medical Center (Tennessee), Ohio State University (Ohio), Wake Forest University (North Carolina), Montefiore Medical Center (New York), Beth Israel Deaconess Medical Center (Massachusetts), Baystate Medical Center (Massachusetts), Intermountain Medical Center (Utah), UCHealth University of Colorado Hospital (Colorado), and Johns Hopkins Hospital (Maryland).

¶ All variates in table were included in multivariable logistic regression model.

** This measured the odds ratio for seroreversion associated with a 1-unit difference in signal-to-threshold ratio value (e.g., 5 versus 4), comparing the higher ratio to the lower ratio.

†† This measured the odds ratio for seroreversion associated with a 10-year difference in age (e.g., 60 years versus 50 years), comparing the higher age to the lower range.

§§ This measured the odds ratio for seroreversion associated with a 1-week difference in time to follow-up (e.g., 9 weeks versus 8 weeks), comparing the later follow-up time to the earlier follow-up time.

¶¶ Medical conditions included one or more of the following: asthma, chronic obstructive pulmonary disease, other chronic lung condition, chronic heart failure, coronary artery disease, diabetes mellitus, hypertension, chronic renal disease (dialysis), autoimmune disease, active cancer (not in remission), immunosuppression (undergoing active chemotherapy or taking a medication to suppress the immune system).

persons who have been infected with SARS-CoV-2 will likely underestimate incidence because a proportion of previously infected persons will likely serorevert and thus not be counted as having been previously infected. In addition, these results challenge the notion of using serologic testing results at an individual level to designate previous SARS-CoV-2 infection. COVID-19 convalescent plasma is widely being used as a treatment for COVID-19, including through a Food and Drug Administration Emergency Use Authorization in the United States (10); these results demonstrate that the optimal window for collecting convalescent plasma with high levels of SARS-CoV-2 antibodies from donors who have recovered from COVID-19 might be short because of substantial

Summary

What is already known about this topic?

Most persons develop virus-specific antibodies to SARS-CoV-2 after infection; however, the timeline of antibody decline over time is uncertain.

What is added by this report?

Among 156 frontline health care personnel who had positive SARS-CoV-2 antibody test results in spring 2020, 94% experienced a decline at repeat testing approximately 60 days later, and 28% seroreverted to below the threshold of positivity. Participants with higher initial antibody responses were more likely to have antibodies detected at the follow-up test than were those who had a lower initial antibody response.

What are the implications for public health practice?


SARS-CoV-2 antibodies decline over weeks following acute infection. Negative SARS-CoV-2 serologic results do not exclude previous infection, which has significant impacts on how serologic studies are interpreted.

decline in antibody levels within 60 days. Whether decline in SARS-CoV-2 antibodies increases risk for reinfection and disease in humans remains unknown. Humoral immunity to primary infections from a novel virus might not be as durable or strong as that to secondary infections, but memory B-cell and T-cell responses might reduce the severity of illness with repeat exposure or infection.

The findings in this report are subject to at least four limitations. First, the timing of the baseline serologic test relative to symptom onset was not standardized, which might affect baseline signal-to-threshold ratios, particularly for recently acquired infection in which antibody levels might still have been increasing. Second, the study population was derived from a convenience sample, which might result in nonrepresentativeness. Third, 38 (20%) participants were lost to follow-up, limiting size of the study population. Finally, misclassification of antibody status was possible; however, this was considered to be unlikely because of the high sensitivity and specificity of the ELISA.

In this study of frontline health care personnel at 13 medical centers who received positive SARS-CoV-2 antibody test results in spring 2020, more than one quarter were seronegative approximately 60 days after testing. Because SARS-CoV-2 antibody levels might decline in a proportion of persons following primary infection, a negative serology test does not reliably exclude previous infection. These antibody declines might not equate to loss of protective immunity or increased risk for reinfection; this was not assessed in this study. Cross-sectional seroprevalence studies to evaluate population immunity are likely to underestimate rates of previous infection because antibodies appear to only be detectable for a discrete period of time following infection.

FIGURE. Percentage of 156 participants with SARS-CoV-2 antibodies at baseline who seroreverted approximately 60 days later, by baseline antibody response* and history of COVID-19-compatible symptoms before baseline testing† — 13 academic medical centers, United States, 2020



Abbreviations: COVID-19 = coronavirus disease 2019; ELISA = enzyme-linked immunosorbent assay.

* Antibody response was categorized as high or low based on signal-to-threshold ratio of panimmunoglobulin reactivity to SARS-CoV-2 full length S protein ELISA at baseline visit.

† Signs and symptoms included one or more of the following reported between February 1, 2020, and the date of baseline study visit: fever (temperature >99.5°F [37.5°C]), cough, shortness of breath, myalgias, sore throat, vomiting, diarrhea, change in or loss of taste or smell, and chest tightness.

CDC COVID-19 Response Team

Mohammed Ata Ur Rasheed, CDC COVID-19 Response Team; Lisa Mills, CDC COVID-19 Response Team; Sandra N. Lester, CDC COVID-19 Response Team; Brandi Freeman, CDC COVID-19 Response Team; Bailey Alston, CDC COVID-19 Response Team; Muiyiwa Ategbale, CDC COVID-19 Response Team; Peter Browning, CDC COVID-19 Response Team; Shanna Bolcen, CDC COVID-19 Response Team; Darbi Boulay, CDC COVID-19 Response Team; Li Cronin, CDC COVID-19 Response Team; Ebenezer David, CDC COVID-19 Response Team; Rita Desai, CDC COVID-19 Response Team; Monica Epperson, CDC COVID-19 Response Team; Yamini Gorantla, CDC COVID-19 Response Team; Tao Jia, CDC COVID-19 Response Team; Pete Maniatis, CDC COVID-19 Response Team; Kristina Ortiz, CDC COVID-19 Response Team; So Hee Park, CDC COVID-19 Response Team; Palak Patel, CDC COVID-19 Response Team; Yunlong Qin, CDC COVID-19 Response Team; Heather Tatum, CDC COVID-19 Response Team; Briana Zellner, CDC COVID-19 Response Team.

IVY Network

Adrienne Baughman, IVY Network; Kimberly W. Hart, IVY Network; Robert McClellan, IVY Network; Rendie McHenry, IVY Network; Jakea Johnson, IVY Network; Andrea Fletcher, IVY Network; Kemberlyne Cordero, IVY Network; Lori Kozikowski, IVY Network; Lesley De Souza, IVY Network; Sarah Romain, IVY Network; Scott Ouellette, IVY Network; Andres Santana, IVY Network; Sherell Thornton-Thompson, IVY Network; Michelle Howell, IVY Network; Jennifer Peers, IVY Network; Shelby Shelton, IVY Network; Lani Finck, IVY Network; Kirsten Soules, IVY Network; Michael Klausner, IVY Network; Ximena Calderon-Morales, IVY Network; Heidi L. Erickson, IVY Network; Audrey Hendrickson, IVY Network; Jamie Stang, IVY Network; Ellen

Maruggi, IVY Network; Alex Dunn, IVY Network; Eddie Stenhjem, IVY Network; Valerie Aston, IVY Network; Mikaele Bown, IVY Network; Michelle Matheu, IVY Network; Rilee Smith, IVY Network; Olivia Krol, IVY Network; Andrew Salar, IVY Network; Makrina Kamel, IVY Network; Kelly Nguyen, IVY Network; Peter Huynh, IVY Network; Sarah Karow, IVY Network; Michelle Bright, IVY Network; Holly Bookless, IVY Network; Sandy Mullins, IVY Network; Kelly Neidert, IVY Network; Dina McGowan, IVY Network; Elizabeth Cassandra, IVY Network; Emily Brown, IVY Network; Claire Carlin, IVY Network; Trina Wemlinger, IVY Network; Breona Edwards, IVY Network; Lori Flores, IVY Network; Mary LaRose, IVY Network; Kathie J. Ferbas, IVY Network; Rachel Martin-Blais, IVY Network; Grace M. Aldrovandi, IVY Network; Olivia Thompson, IVY Network; Sakshi Sehgal, IVY Network.

Corresponding author: Wesley H. Self, wesley.self@vumc.org.

¹Vanderbilt University Medical Center, Nashville, Tennessee; ²CDC COVID-19 Response Team; ³Baystate Medical Center, Springfield, Massachusetts; ⁴Beth Israel Deaconess Medical Center, Boston, Massachusetts; ⁵University of Colorado School of Medicine, Aurora, Colorado; ⁶Hennepin County Medical Center, Minneapolis, Minnesota; ⁷Intermountain Medical Center and University of Utah School of Medicine, Salt Lake City, Utah; ⁸Montefiore Medical Center, Bronx, New York; ⁹Oregon Health & Science University Hospital, Portland, Oregon; ¹⁰Ohio State University Wexner Medical Center, Columbus, Ohio; ¹¹Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina; ¹²Johns Hopkins Hospital, Baltimore, Maryland; ¹³UCLA Medical Center, Los Angeles, California; ¹⁴Harborview Medical Center, Seattle, Washington.

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Christopher J. Lindsell reports grants from National Institutes of Health, grants from Department of Defense, Marcus Foundation, Endpoint Health, Entegriion, bioMerieux, and Bioscape Digital, outside the submitted work. Daniel J. Henning reports personal fees from CytoVale and grants from Baxter, outside the submitted work. Akram Khan reports grants

from United Therapeutics, Actelion Pharmaceuticals, Regeneron, and Reata Pharmaceuticals, outside the submitted work. Samuel M. Brown reports grants from National Institutes of Health, Department of Defense, Intermountain Research and Medical Foundation, and Janssen; consulting fees paid to his employer from Faron and Sedana, all outside the submitted work. Ithan D. Peltan reports grants from the National Institutes of Health and, outside the submitted work, grants from Asahi Kasei Pharma, Immunexpress Inc., Janssen Pharmaceuticals, and Regeneron. Carlos Grijalva reports other from Pfizer, other from Merck, other from Sanofi-Pasteur, grants from Campbell Alliance, the National Institutes of Health, the Food and Drug Administration, the Agency for Health Care Research and Quality, outside the submitted work. Todd W. Rice reports consulting work for Cumberland Pharmaceuticals, Inc, outside the submitted work. H. Keipp Talbot has served on a data safety and monitoring board for Seqirus. Natasha Halasa receives grant support from Quidel and Sanofi, donation of vaccines and hemagglutination inhibition/microneutralization titers performed by Sanofi, and speaker fees by an educational grant supported by Genentech, outside the submitted work. No other potential conflicts of interest were disclosed.

References

1. Self WH, Tenforde MW, Stubblefield WB, et al.; CDC COVID-19 Response Team; IVY Network. Seroprevalence of SARS-CoV-2 among frontline health care personnel in a multistate hospital network—13 academic medical centers, April–June 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:1221–6. PMID:32881855 <https://doi.org/10.15585/mmwr.mm6935e2>
2. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. *Clin Infect Dis* 2020;ciaa344. PMID:32221519 <https://doi.org/10.1093/cid/ciaa344>
3. Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat Med* 2020;26:845–8. PMID:32350462 <https://doi.org/10.1038/s41591-020-0897-1>
4. Havers FP, Reed C, Lim T, et al. Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States, March 23–May 12, 2020. *JAMA Intern Med* 2020. Epub July 21, 2020. <https://doi.org/10.1001/jamainternmed.2020.4130>
5. Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. *Lancet* 2020;396:313–9. PMID:32534626 [https://doi.org/10.1016/S0140-6736\(20\)31304-0](https://doi.org/10.1016/S0140-6736(20)31304-0)
6. Anand S, Montez-Rath M, Han J, et al. Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study. *Lancet* 2020;396:1335–44. PMID:32987007 [https://doi.org/10.1016/S0140-6736\(20\)32009-2](https://doi.org/10.1016/S0140-6736(20)32009-2)
7. Crawford KHD, Dings AS, Eguia R, et al. Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. *J Infect Dis* 2020;jiaa618. PMID:33000143 <https://doi.org/10.1093/infdis/jiaa618>
8. Patel MM, Thornburg NJ, Stubblefield WB, et al. Change in antibodies to SARS-CoV-2 over 60 days among health care personnel in Nashville, Tennessee. *JAMA* 2020;324:1781–2. PMID:32940635 <https://doi.org/10.1001/jama.2020.18796>
9. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. *N Engl J Med* 2020;383:1085–7. PMID:32706954 <https://doi.org/10.1056/NEJMc2025179>
10. Food and Drug Administration. Emergency use authorization declaration. Washington, DC: US Department of Health and Human Services, Food and Drug Administration; 2020. <https://www.fda.gov/media/141477/download>